TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07688213: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 48-week SAR448851 Treatment Followed by Open-label Extension in Participants With Early Alzheimer's Disease

Sponsor: Sanofi · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$7,954,000

Rescue Site Savings

+$5,238,000

Unlock Full NCT07688213 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07688213 Rescue Dossier →